|
|
| |
 |
 |
Floxuridine inhibits 96% of
colorectal cancer cells (HT-96 cell line) versus
5-FU, which only inhibits 50%.1 Advances in how
to optimize the clinical effects of this established
chemotherapy agent have resulted in innovative
treatment strategies. Clinical experience involving
weekly high dose intravenous floxuridine regimens
has demonstrated excellent results in treating
pancreatic and colorectal cancers.
Patients can receive high dose
treatment as a 24 hour continuous infusion administered
once a week from the comfort of their own home.
With side effects similar to 5-FU, floxuridine
is well tolerated. Extending the infusion interval
to 24 hours significantly reduces the adverse
event profile of floxuridine.
Improving the effectiveness
of a treatment regimen and limiting side effects
should be one of your highest considerations when
selecting a patient-specific chemotherapy regimen.
Many patients who have failed current conventional
chemotherapics have experienced dramatic improvements
in both quality of life and extended survival
rates when treated with Floxuridine.
*Chabner BA, et al. Antineoplastic
Agents. In: Goodman and Gilman’s: The Pharmacologic
Basis of Therapeutics. 10th Edition. McGraw-Hill,
New York; 2001. 1389-1459.
|
|
 |
|
| |
|
|
